UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Diabetes care, 2018-12, Vol.41 (12), p.2560-2569

2018

Volltextzugriff (PDF)

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

Diabetes care, 2014-05, Vol.37 (5), p.1480-1483

2014

Volltextzugriff (PDF)

Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1

American journal of physiology. Regulatory, integrative and comparative physiology, 2006-10, Vol.291 (4), p.R1085-R1093

2006

Volltextzugriff (PDF)

Molecular Evidence of Placental Hypoxia in Preeclampsia

The journal of clinical endocrinology and metabolism, 2005-07, Vol.90 (7), p.4299-4308

2005

Volltextzugriff (PDF)

TRPC6 Inhibitor BI 764198 in Focal Segmental Glomerulosclerosis: Phase 2 Study Design

Kidney international reports, 2023-12, Vol.8 (12), p.2822-2825

2023

Volltextzugriff (PDF)

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes

PloS one, 2015-11, Vol.10 (11), p.e0141085-e0141085

2015

Volltextzugriff (PDF)

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes

Pharmaceutics, 2021-04, Vol.13 (4), p.485

2021

Volltextzugriff (PDF)

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

Circulation (New York, N.Y.), 2014-02, Vol.129 (5), p.587-597

2014

Volltextzugriff (PDF)

Patient preferences for newer oral therapies in type 2 diabetes

International journal of cardiology, 2023-01, Vol.371, p.526-532

2023

Volltextzugriff (PDF)

Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review

BMJ open, 2017-07, Vol.7 (7), p.e016587-e016587

2017

Volltextzugriff (PDF)

Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition

Circulation (New York, N.Y.), 2022-08, Vol.146 (6), p.450-462

2022

Volltextzugriff (PDF)

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

Cardiovascular diabetology, 2014-01, Vol.13 (1), p.28-28

2014

Volltextzugriff (PDF)

Kidney Effects of Empagliflozin in People with Type 1 Diabetes

Clinical journal of the American Society of Nephrology, 2021-11, Vol.16 (11), p.1715-1719

2021

Volltextzugriff (PDF)

2216-PUB: Patient Preferences for Newer Oral Therapies in Type 2 Diabetes

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

Diabetologia, 2014-12, Vol.57 (12), p.2599-2602

2014

Volltextzugriff (PDF)

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

Kidney international, 2020-04, Vol.97 (4), p.631-635

2020

Volltextzugriff (PDF)

TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial

Thorax, 2023-08, Vol.78 (8), p.816-824

2023

Volltextzugriff (PDF)

20-OR: The Renal and Vascular Effects of Combined SGLT2 and Angiotensin Converting Enzyme Inhibition

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial

Diabetes, obesity & metabolism, 2018-09, Vol.20 (9), p.2190-2199

2018

Volltextzugriff (PDF)

Kidney Effects of Empagliflozin in People with Type 1 Diabetes: PO1008

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.345-345

2020

Volltextzugriff (PDF)

Population Pharmacokinetic– Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus

Journal of clinical pharmacology, 2018-05, Vol.58 (5), p.640-649

2018

Volltextzugriff (PDF)

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes

Kidney international, 2014-11, Vol.86 (5), p.1057-1058

2014

Volltextzugriff (PDF)

Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1)

Diabetes technology & therapeutics, 2017-01, Vol.19 (1), p.49-60

2017

Volltextzugriff (PDF)

994-P: DINAMO—Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents with Type 2 Diabetes (T2D) : Innovative Study Design and Baseline Characteristics

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes

Diabetes care, 2019-09, Vol.42 (9), p.1716-1723

2019

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(34)
Dissertationen
(2)

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Life Sciences & Biomedicine
(23)
Humans
(19)
Diabetes
(17)
Adult
(13)
Insulin
(13)
Female
(12)
Diabetes Mellitus
(11)
Diabetes Mellitus, Type 1 - Drug Therapy
(10)
Endocrinology & Metabolism
(9)
Glucose
(9)
Male
(8)
Biological And Medical Sciences
(7)
Clinical Trials
(7)
Hypoglycemia
(7)
Benzhydryl Compounds - Therapeutic Use
(6)
Glucosides - Therapeutic Use
(6)
Hypoglycemic Agents - Therapeutic Use
(6)
Benzhydryl Compounds - Pharmacology
(5)
Blood Pressure
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1

Molecular Evidence of Placental Hypoxia in Preeclampsia

TRPC6 Inhibitor BI 764198 in Focal Segmental Glomerulosclerosis: Phase 2 Study Design

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

Patient preferences for newer oral therapies in type 2 diabetes

Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review

Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

Kidney Effects of Empagliflozin in People with Type 1 Diabetes

2216-PUB: Patient Preferences for Newer Oral Therapies in Type 2 Diabetes

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial

20-OR: The Renal and Vascular Effects of Combined SGLT2 and Angiotensin Converting Enzyme Inhibition

Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial

Kidney Effects of Empagliflozin in People with Type 1 Diabetes: PO1008

Population Pharmacokinetic– Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes

Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1)

994-P: DINAMO—Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents with Type 2 Diabetes (T2D) : Innovative Study Design and Baseline Characteristics

Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes

Suchergebnisse filtern